Subcutaneous low-dose azacitidine as maintenance therapy following hematopoietic stem cell transplantation for acute myeloid leukemia and high-risk myelodysplastic syndrome-A propensity score matched analysis

Hematol Transfus Cell Ther. 2024 Dec:46 Suppl 6:S427-S430. doi: 10.1016/j.htct.2024.03.006. Epub 2024 May 25.
No abstract available

Publication types

  • Letter